About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: RARE
- Previous Close: $76.92
- 50 Day Moving Average: $73.16
- 200 Day Moving Average: $70.87
- 52-Week Range: $46.52 - $86.77
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.22
- P/E Growth: -0.37
- Market Cap: $3.19B
- Outstanding Shares: 40,859,000
- Beta: 1.83
- Return on Equity: -46.68%
- Return on Assets: -43.12%
Companies Related to Ultragenyx Pharmaceutical:
- Current Ratio: 8.26%
- Quick Ratio: 8.26%
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?
14 equities research analysts have issued 12-month price targets for Ultragenyx Pharmaceutical's stock. Their forecasts range from $64.00 to $109.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $92.25 in the next twelve months.
When will Ultragenyx Pharmaceutical announce their earnings?
Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
Cowen and Company analysts commented, "Ultragenyx reported a Q4 net loss of $71MM and ended the quarter with cash of." (2/17/2017)
- Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)
According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/12/2017)
Leerink Swann analysts commented, "We maintain our OP rating on RARE with PT $85. A 64.8%/70.6% reduction in uGAGs (p50%/>60% reduction in dermatan and chondroitin sulfate (both uGAGs) within the first 2 weeks that was maintained until 24 weeks. Despite investors’ concerns of a small trial (n=12), 4 mg/kg rhGUS effectively demonstrated its efficacy as an enzyme in removing the accumulated substrate in MPS VII pts. Although the aggregate of functional improvements narrowly missed stat. sig. (p=0.0527), we believe clinical improvements engenderd by rhGUS makes a strong case for the therapy. The summation of scores from functional assessments (including 6-minute walk test/6MWT and visual acuity) showed a positive trend. With regards to the miss on stat. sig., we agree with mgmt. that individual assessments paint a clearer picture of therapeutic benefit in pts. and remind investors that neither regulatory agencies required stat. sig. in earlier discussions. Furthermore, whereas functionality in pts. progressively worsen, noteworthy improvements in 6MWT (especially 60+ meters benefit in 3/9 pts. over 24 weeks) and ~2/3 of pts." (7/15/2016)
Who owns Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.40%), State Street Corp (3.42%), Columbia Wanger Asset Management LLC (2.88%), Capital Guardian Trust Co. (1.40%), Federated Investors Inc. PA (1.07%) and Brown Advisory Inc. (0.73%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, State Street Corp, FMR LLC, Highland Capital Management LP, Allianz Asset Management AG, Guggenheim Capital LLC, Federated Investors Inc. PA and Trexquant Investment LP. Company insiders that have sold Ultragenyx Pharmaceutical stock in the last year include Emil D Kakkis, Shalini Sharp, Sunil Agarwal and William Aliski.
Who bought Ultragenyx Pharmaceutical stock? Who is buying Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Capital Guardian Trust Co., Fred Alger Management Inc., Teachers Retirement System of The State of Kentucky, Brown Advisory Inc., Russell Investments Group Ltd., Capital International Inc. CA, Dimensional Fund Advisors LP and Capital International Ltd. CA.
How do I buy Ultragenyx Pharmaceutical stock?
Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ultragenyx Pharmaceutical stock cost?
One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $78.18.